Daré Bioscience (DARE) 10-Q 13 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 09, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	DARE
Entity Registrant Name	Dare Bioscience, Inc.
Entity Central Index Key	1,401,914
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock Shares Outstanding		11,422,161

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 9,537,463	$ 7,559,846
Other receivables	80,278	284,206
Prepaid expenses	549,949	311,571
Other current assets		193,495
Total current assets	10,167,690	8,349,118
Property and equipment, net	10,572
Goodwill		5,187,519
Other non-current assets	617,499	723,191
Total assets	10,795,761	14,259,828
Current liabilities
Accounts payable and accrued expenses	1,202,912	966,653
Total current liabilities	1,202,912	966,653
Deferred rent	9,292	392
Total liabilities	1,212,204	967,045
Commitments and contingencies (Note 8)
Stockholders' equity (deficit)
Preferred stock, $0.01 par value, 5,000,000 shares authorized None issued and outstanding
Common stock: $0.0001 par value, 120,000,000 shares authorized, 11,422,161 and 6,047,161 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	1,142	605
Accumulated other comprehensive loss	(78,032)	(18,080)
Additional paid-in capital	35,713,662	25,541,210
Accumulated deficit	(26,053,215)	(12,230,952)
Total stockholders' equity	9,583,557	13,292,783
Total liabilities and stockholders' equity	$ 10,795,761	$ 14,259,828

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	11,422,161	6,047,161
Common stock, shares outstanding	11,422,161	6,047,161

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating expenses:
General and administrative	$ 1,175,049	$ 1,052,628	$ 3,635,413	$ 1,729,338
Research and development expenses	1,446,548	280,793	4,750,823	312,169
License expenses			350,000
Impairment of goodwill			5,187,519
Total operating expenses	2,621,597	1,333,421	13,923,755	2,041,507
Loss from operations	(2,621,597)	(1,333,421)	(13,923,755)	(2,041,507)
Other income (expense)	47,122	(296,262)	101,492	(330,233)
Net loss	(2,574,475)	(1,629,683)	(13,822,263)	(2,371,740)
Foreign currency translation adjustments	(18,721)	(9,774)	(59,952)	(9,774)
Comprehensive loss	$ (2,593,196)	$ (1,639,457)	$ (13,882,215)	$ (2,381,514)
Loss per common share - basic and diluted	$ (0.23)	$ (0.33)	$ (1.32)	$ (1.04)
Weighted average number of common shares outstanding:
Basic and diluted	11,422,161	4,986,226	10,499,982	2,283,673

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities:
Net loss	$ (13,822,263)	$ (2,371,740)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,263
Stock-based compensation	58,538	6,953
Non-cash interest		316,804
Acquired in-process research and development	507,000
Impairment of goodwill	5,187,519
Changes in operating assets and liabilities, net impact of acquisition:
Other receivables	203,928
Prepaid expenses	(238,378)	(224,433)
Other current assets	193,495
Other non-current assets and deferred charges	105,692	(2,800)
Accounts payable and accrued expenses	236,259	659,223
Interest payable		36,776
Deferred rent	8,900	157
Net cash used in operating activities	(7,558,047)	(1,579,060)
Investing activities:
Cash acquired through merger		9,918,440
Purchases of property and equipment	(11,836)
Acquisition of Pear Tree and Hydra asset	(507,000)
Net cash provided by (used in) investing activities	(518,836)	9,918,440
Financing activities:
Net proceeds from issuance of common stock and warrants	10,114,452
Proceeds from issuance of convertible promissory notes		155,000
Net cash provided by financing activities	10,114,452	155,000
Effect of exchange rate changes on cash and cash equivalents	(59,952)	(9,774)
Net change in cash and cash equivalents	1,977,617	8,484,606
Cash and cash equivalents, beginning of period	7,559,846	44,614
Cash and cash equivalents, end of period	$ 9,537,463	$ 8,529,220

Organization and Description of

Organization and Description of the Business	9 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of the Business	1. Daré Bioscience, Inc., is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. Daré Bioscience, Inc. and its wholly owned subsidiaries, Daré Bioscience Operations, Inc., Daré Bioscience Australia Pty LTD, and Pear Tree Pharmaceuticals, Inc., operate in one segment. In this report, the “Company” refers collectively to Daré Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires. The Company is driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. The Company’s business strategy is to license or otherwise acquire the rights to differentiated reproductive health product candidates, some of which have existing clinical proof-of-concept data, and to take those candidates through advanced stages of clinical development or regulatory approval. The Company has assembled a portfolio of clinical-stage and preclinical-stage candidates addressing unmet needs in women’s reproductive health. The Company’s two clinical-stage assets—Ovaprene ® and Sildenafil Cream, 3.6%—were obtained through product license and development agreements. Ovaprene, was licensed in July of 2017 and was in February of 2018. In March of 2018, the Company entered into a collaboration and option agreement covering new injectable contraceptive product candidates; in April of 2018, the Company licensed the worldwide rights to a portfolio of preclinical intravaginal rings; in May of 2018, the Company acquired a company that owns the rights to a related to a novel target for non-hormonal contraceptives for both men and women. The Company’s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through late-stage clinical development or regulatory approval. The Company has not generated any revenue related to its primary business purpose to date and is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key individuals, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.

Liquidity

Liquidity	9 Months Ended
	Sep. 30, 2018
Liquidity [Abstract]
Liquidity	2. The Company has a history of losses from operations and anticipates that it will continue to incur losses for at least the next several years. For the nine months ended September 30, 2018, the Company incurred a net loss of $13.8 million. At September 30, 2018, the Company had an accumulated deficit of approximately $26.1 million and had cash and cash equivalents of approximately $9.5 million. The Company also had negative cash flow from operations of approximately $7.6 million during the nine months ended September 30, 2018. During the first quarter of 2018, the Company received gross proceeds of approximately $11.3 million, resulting in net proceeds of approximately $10.1 million, from sales of its securities in registered offerings (see Note 7). During the third quarter, the Company received approximately $144,000 from a federal grant. The Company is focused primarily on the development and commercialization of innovative products in women’s reproductive health. T any of such that As of the date of current Although the Company has cash and cash equivalents of approximately $9.5 million at September 30, 2018, the Company will need to raise additional capital through financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The Company cannot be sure that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company or its stockholders. The interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Significant Accounting Policies	3. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 1 to the interim consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission, or SEC on March 28, 2018. Since the date of those financial statements, there have been no material changes to the Company’s significant accounting policies, except as described below. Basis of Presentation The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Reverse Stock Split On July 20, 2017, the Company effected a of its common stock. Use of Estimates Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of stock-based compensation, goodwill impairment and purchase accounting. Actual results could differ from those estimates and could materially affect the reported amounts of assets, liabilities and future operating results. Principles of Consolidation The interim consolidated financial statements of the Company are stated in U.S. dollars and are prepared using GAAP. These financial statements include the accounts of the Company and its wholly owned subsidiaries, Daré Bioscience Operations, Inc., Daré Bioscience Australia Pty LTD, and Pear Tree Pharmaceuticals, Inc. The financial statements of the Company’s wholly owned subsidiaries are recorded in their functional currency and translated into the reporting currency. The cumulative effect of changes in exchange rates between the foreign entity’s functional currency and the reporting currency is reported in accumulated other comprehensive loss in the interim consolidated balance sheets. All significant intercompany transactions and accounts have been eliminated in consolidation. Grant Funding The Company receives certain research and development funding through a grant issued by a division of the National Institutes of Health. The funding is recognized in the statement of operations as a reduction to research and development expense as the related costs are incurred to meet those obligations over the grant period. The Company adopted this policy in 2018. During the three and nine months ended September 30, 2018, the Company recognized approximately $213,000 in the statement of operations as a reduction to research and development expense. Fair Value Measurements GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows: • Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities. • Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Cash and cash equivalents of $9.5 million and $7.6 million measured at fair value as of September 30, 2018 and December 31, 2017, respectively, are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities. Recent Pronouncements Not Yet Adopted In February 2016, FASB issued ASU 2016-02, Leases (Topic 842) Recently Adopted Accounting Standards In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments , which intended to add or clarify guidance on the classification of certain cash receipts and payments on the statement of cash flows. The new guidance addresses cash flows related to: debt prepayment or extinguishment costs, settlement of zero-coupon bonds, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies and bank-owned life insurance policies, distributions received from equity method investees, beneficial interest in securitization transactions, and the application of predominance principle to separately identifiable cash flows. The standard became effective on January 1, 2018. The Company’s adoption of this standard on January 1, 2018 did not have a material impact on the Company’s interim consolidated financial statements. In January 2017, FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In January 2017, FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350) In May 2017, FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (I) Accounting for Certain Financial Instruments with Down Round Features, (II) Replacement for the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Acquisitions	4. Acquisitions Cerulean/Private Dare Stock Purchase Transaction On July 19, 2017, the Company completed its business combination with Daré Bioscience Operations, Inc., a privately held Delaware corporation, or Private Daré, in accordance with the terms of the Stock Purchase Agreement dated as of March 19, 2017, or the Daré Stock Purchase Agreement, by and among the Company, Private Daré and the holders of capital stock and securities convertible into capital stock of Private Daré named therein, or the Private Daré Stockholders. Pursuant to the Daré Stock Purchase Agreement, each Private Daré Stockholder sold their shares of capital stock in Private Daré to the Company in exchange for newly issued shares of the Company’s common stock, and as a result, Private Daré became a wholly owned subsidiary of the Company and the Private Daré Stockholders became majority stockholders of the Company. In connection with the closing of that transaction, the Company changed its name from “Cerulean Pharma Inc.” to “Daré Bioscience, Inc.” In this report, that transaction is referred to as the Cerulean/Private Daré stock purchase transaction and “Cerulean” refers to Cerulean Pharma Inc. before that transaction closed. The Cerulean/Private Daré stock purchase transaction was accounted for as a reverse merger under the acquisition method of accounting whereby Private Daré was considered to have acquired Cerulean for financial reporting purposes because immediately upon completion of the transaction, Private Daré stockholders held a majority of the voting interest of the combined company. Pursuant to business combination accounting, the Company applied the acquisition method, which requires the assets acquired and liabilities assumed be recorded at fair value with limited exceptions. The excess of the purchase price over the assets acquired and liabilities assumed represents goodwill. The goodwill is primarily attributable to the cash and cash equivalents at closing of the transaction of approximately $9.9 million and the impact of the unamortized fair value of stock options granted by Cerulean that were outstanding immediately before the transaction closed of approximately $3.7 million. The unamortized fair value of such stock options relates to an option modification approved on March 19, 2017 that provided for an acceleration of vesting of such options upon a change in control event. Such modification became effective upon the closing of the Cerulean/Private Daré stock purchase transaction. Hence, the unamortized fair value of such stock options is deemed to be part of total purchase consideration and goodwill. Transaction costs associated with the Cerulean/Private Daré stock purchase transaction of $0.96 million are included in general and administrative expense. The total purchase price consideration of approximately $24.3 million represents the fair value of the shares of Cerulean stock issued in connection with the Cerulean/Private Daré stock purchase transaction and the unamortized fair value of the stock options described above, which was allocated as follows: Purchase Consideration (in thousands) Fair value of shares issued $ 20,625 Unamortized fair value of Cerulean options 3,654 Fair value of total consideration $ 24,279 Assets acquired and liabilities assumed Cash and cash equivalents $ 9,918 Prepaid expense and other current assets 1,915 Accounts payable (233 ) Total assets acquired and liabilities assumed 11,600 Goodwill $ 12,679 The final allocation of the purchase price depended on finalizing the valuation of the fair value of assets acquired and liabilities assumed. The Company retrospectively recorded purchase price adjustments at the acquisition date to increase current liabilities and current assets by $23,609 and $225,778, respectively, which reduced the original goodwill amount of $12.9 million by $202,169. The Company tests its goodwill for impairment at least annually as of December 31 and between annual tests if it becomes aware of an event or change in circumstance that would indicate the carrying value may be impaired. The Company tests goodwill for impairment at the entity level because it operates on the basis of a single reporting unit. A goodwill impairment is the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. When impaired, the carrying value of goodwill is written down to fair value. Any excess of the reporting unit goodwill carrying value over the fair value is recognized as impairment loss. The Company assessed goodwill at December 31, 2017. The Company determined there was an impairment and recognized an impairment charge of approximately $7.5 million in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2017 and reduced the goodwill carrying value from approximately $12.7 million to $5.2 million on its consolidated balance sheet as of December 31, 2017. The Company assessed goodwill at March 31, 2018, determined there was an impairment and recognized an impairment charge of approximately $5.2 million in the interim consolidated statement of operations and comprehensive loss for the three months ended March 31, 2018. As of March 31, 2018, the goodwill carrying value on the Company’s consolidated balance sheet was written off in its entirety. Pear Tree Merger On April 30, 2018, the Company entered into an Agreement and Plan of Merger, the Merger Agreement, with Pear Tree Pharmaceuticals, Inc., or Pear Tree, Daré Merger Sub, Inc., a wholly-owned subsidiary of the Company, or Merger Sub, and two individuals in their respective capacities as Pear Tree stockholders’ representatives. The transactions contemplated by the Merger Agreement closed on May 16, 2018, and as a result, Pear Tree became the Company’s wholly owned subsidiary. The Company acquired Pear Tree to secure the rights to develop DARE-VVA1, a proprietary vaginal formulation of tamoxifen, as a potential treatment for vulvar and vaginal atrophy. The Company determined that the acquisition of Pear Tree should be accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset is not considered a business. Transaction costs of approximately $452,000 associated with the merger are included in the Company’s research and development expense. In accordance with the terms of the Merger Agreement, because the Negative Consideration Amount (as defined below) exceeded the Positive Consideration Amount (as defined below), at the time of the closing of the merger, the excess amount (approximately $132,000) will be offset against future payments otherwise due under the Merger Agreement to certain former and continuing Pear Tree service providers and former holders of Pear Tree’s capital stock, or the Holders, including the potential $75,000 payment due on the one-year anniversary of the closing of the merger. Positive Consideration Amount means the sum of $75,000, and the cash and cash equivalents held by Pear Tree at closing, and Negative Consideration Amount means the sum of (i) certain Pear Tree indebtedness and transaction expenses, (ii) transaction expenses of the stockholders’ representatives, and (iii) amounts payable under Pear Tree’s management incentive plan. Under the Merger Agreement, the Holders will be eligible to receive, subject to certain offsets, tiered royalties, including customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue. The Company must also make contingent payments to the Holders that are based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company’s sole discretion, in cash or shares of the Company’s common stock.

Convertible Promissory Notes

Convertible Promissory Notes	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Convertible Promissory Notes	5. Convertible Promissory Notes Prior to the Cerulean/Private Daré stock purchase transaction, Private Daré financed its operations through the sale of convertible promissory notes that entitled the holder to accrued interest at an annual rate of 8%. In the event of a preferred stock financing by Private Daré, all outstanding principal and unpaid interest under the convertible promissory notes would have converted into the shares of Private Daré’s preferred stock issued in such financing at the price per share paid by the purchasers of such shares and an additional number of shares equal to, depending on the time of purchase, 20% to 40% of the outstanding principal and unpaid interest, or the conversion benefit. Private Daré issued a convertible promissory note in the principal amount of $100,000 in February 2017 and issued additional convertible promissory notes in the aggregate principal amount of $55,000 between April 1, 2017 and June 6, 2017. In connection with the Cerulean/Private Daré stock purchase transaction, all outstanding convertible promissory notes were amended to provide that their principal amount plus accrued interest and taking into account their conversion benefit, would convert into shares of Private Daré common stock immediately prior to the closing of the Cerulean/Private Daré stock purchase transaction. The number of shares of Private Daré common stock issued upon conversion of the convertible promissory notes issued before March 31, 2017 was equal to (i) their outstanding principal amount plus accrued interest through March 31, 2017 multiplied by the respective conversion benefit, which ranged from 125% to 140%, divided by (ii) $0.18727. The number of shares of Private Daré common stock issued upon conversion of the convertible promissory notes issued after March 31, 2017 was equal to (i) 120% of their outstanding principal amount, divided by (ii) $0.38. In connection with the closing of the Cerulean/Private Daré stock purchase transaction, all the outstanding shares of Private Daré common stock, including the shares issued upon conversion of the above described convertible promissory notes, were exchanged for shares of the Company’s common stock at the exchange ratio specified in the Daré Stock Purchase Agreement. The Company recognized interest expense of $0 and $316,804 at September 30, 2018 and September 30, 2017, respectively, relating to the convertible promissory notes.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	6. Stock-based Compensation The 2015 Employee, Director and Consultant Equity Incentive Plan Prior to the Cerulean/Private Daré stock purchase transaction, the 2015 Employee, Director and Consultant Equity Incentive Plan of Private Daré, or the 2015 Private Daré Plan, governed the issuance of equity awards to Private Daré employees, officers, non-employee directors and consultants. Options granted under the 2015 Private Daré Plan have terms of ten years from the date of grant unless earlier terminated and generally vest over a three-year period. Upon closing of the Cerulean/Private Daré stock purchase transaction, the Company assumed the 2015 Private Daré Plan and each outstanding option to acquire Private Daré stock that was not exercised prior to the closing. Options to purchase 50,000 shares of Private Daré stock were assumed. Such options were assumed on the same terms as were applicable to them under the 2015 Private Daré Plan and became an option to purchase such number of shares of the Company’s common stock equal to the number of Private Daré shares subject to such option multiplied by the exchange ratio specified in the Daré Stock Purchase Agreement, at a correspondingly adjusted exercise price. Based on the exchange ratio and after giving effect to the reverse stock split effected in connection with the closing of the Cerulean/Private Daré stock purchase transaction, such options were replaced with options to purchase 10,149 shares of the Company’s common stock, all of which were outstanding as of September 30, 2018. Private Daré issued 900,000 and 200,000 shares of fully vested restricted stock to non-employees under the 2015 Private Daré Plan during 2015 and 2016, respectively. In connection with the closing of the Cerulean/Private Daré stock purchase transaction, the Company assumed these shares and replaced them with 223,295 restricted shares of the Company’s common stock (after giving effect to the reverse stock split effected in connection with the closing of the Cerulean/Private Daré stock purchase transaction). No further awards may be granted under the 2015 Private Daré Plan following the closing of the Cerulean/Private Daré stock purchase transaction. 2014 Employee Stock Purchase Plan In March 2014, the Company’s board of directors adopted, and its stockholders approved the 2014 Employee Stock Purchase Plan, or the ESPP, which became effective in April 2014. The ESPP permits eligible employees to enroll in a six-month offering period whereby participants may purchase shares of the Company’s common stock, through payroll deductions, at a price equal to 85% of the closing price of the common stock on the first day of the offering period or on the last day of the offering period, whichever is lower. Purchase dates under the ESPP occur on or about June 30 and December 31 each year. The Company’s board of directors decided not to initiate a new offering period beginning January 1, 2017 and no offering period has been initiated since then. There was no stock-based compensation related to the ESPP for the nine months ended September 30, 2018 or September 30, 2017. Amended and Restated 2014 Stock Incentive Plan The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan, which was approved by the Company’s stockholders on July 10, 2018. The Amended 2014 Plan was an amendment and restatement of the Company’s 2014 Stock Incentive Plan, or the 2014 Plan. The number of shares authorized for issuance under the Amended 2014 Plan is 2,046,885, which is the sum of (a) 1,509,463 shares of common stock plus (b) 537,422 shares of common stock subject to awards granted under the 2014 Plan. The number of authorized shares will increase annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) 2,000,000, (ii) 4% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company’s board of directors. In March 2017, the Company’s board of directors approved two modifications to outstanding stock options granted under the 2014 Plan to participants providing services to the Company as of that date. One modification extended the exercise period of such stock options to two years after such participant’s termination date, unless the exercise period absent such modification would be longer. The other modification provided for accelerated vesting of such stock options upon a change in control event. These modifications resulted in unamortized fair value expense of approximately $3.7 million and was recorded as part of the total consideration in the Cerulean/Private Daré stock purchase transaction (see Note 4). At September 30, 2018, 451,244 shares of common stock were reserved for future issuance under the Amended 2014 Plan, and options to purchase 1,605,790 shares of the Company’s common stock granted under the Amended 2014 Plan were outstanding. Summary of Stock Option Activity The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the nine months ended September 30, 2018. The exercise price of all options granted during the nine months ended September 30, 2018 was equal to the market value of the Company’s common stock on the date of the grant. As of September 30, 2018, unamortized stock-based compensation expense of $1,089,491 will be amortized over a weighted average period of 3.6 years. Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2017 (1) 539,896 $ 31.40 Granted 1,066,050 1.09 Exercised — — Cancelled/expired (156 ) 59.48 Outstanding at September 30, 2018 (unaudited) 1,605,790 $ 11.27 Exercisable at September 30, 2018 (unaudited) 535,031 $ 31.62 (1) Includes 10,149 shares subject to options granted under the 2015 Private Daré Plan assumed in connection with the Cerulean/Private Daré stock purchase transaction. Compensation Expense Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows: Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Research and development $ 5,494 $ — $ 5,994 $ — General and administrative 34,497 6,947 52,544 6,953 Total $ 39,991 $ 6,947 $ 58,538 $ 6,953 The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three and nine months ended September 30, 2018 are as follows: Three Months Ended Nine Months Ended September 30, 2018 September 30, 2018 Expected life in years 10.0 10.0 Risk-free interest rate 2.90% 2.90% Expected volatility 123% 123% Forfeiture rate 0.0% 0.0% Dividend yield 0.0% 0.0% Weighted-average fair value of options granted $ 1.03 $ 1.04 Restricted Stock After the Cerulean/Private Daré Stock Purchase Transaction The 3.14 million shares of common stock issued in connection with the Cerulean/Private Daré stock purchase transaction to the Private Daré stockholders were not registered with the SEC and may only be sold if registered under the Securities Act of 1933, as amended, or pursuant to an exemption from the registration requirements thereunder. The shares held by non-affiliates became eligible for sale under Rule 144 beginning .

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity ATM Sales Agreement In January 2018, the Company entered into a common stock sales agreement under which the Company may sell up to an aggregate of $10 million in gross proceeds through the sale of shares of common stock from time to time in “at-the-market” equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended), including in sales made directly on the Nasdaq Capital Market, or Nasdaq, to or through a market maker or, subject to our prior approval, in negotiated transactions. The Company agreed to pay a commission of up to 3% of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. The common stock sales agreement was amended in August 2018 to refer to the Company’s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company’s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018. During the nine months ended September 30, 2018, the Company issued and sold 375,000 shares under the common stock sales agreement for gross proceeds of approximately $1.0 million and incurred offering expenses of approximately $336,000. All such shares were sold during January and February 2018. Underwritten Public Offering In February 2018, the Company closed an underwritten public offering of 5.0 million shares of its common stock and warrants to purchase up to 3.5 million shares of its common stock. Each share of common stock was sold with a warrant to purchase up to 0.70 of a share of the Company’s common stock. The Company granted the underwriter a 30-day overallotment option to purchase up to an additional 750,000 shares of common stock and/or warrants to purchase up to 525,000 shares of common stock. The underwriter exercised the option with respect to warrants to purchase 220,500 shares of common stock. The Company received gross proceeds of $10.3 million, including the proceeds from the sale of the warrants upon exercise of the underwriter’s overallotment option, and net proceeds of approximately $9.4 million. Common Stock Warrants The warrants issued in the February 2018 underwritten offering have an exercise price of $3.00 per share and are exercisable immediately and for five years from issuance. The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be adjusted downward if the Company issues or sells (or is deemed to issue or sell) securities at a price that is less than the exercise price in effect immediately prior to such issuance or sale (or deemed issuance or sale). In that case, the exercise price of the warrants will be adjusted to equal the price at which the new securities are issued or sold (or are deemed to have been issued or sold). In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company’s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. The warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. The Company has estimated the fair value of the warrants as of February 15, 2018 to be approximately $3.0 million which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 and as a result has recorded the fair value of the warrants as equity (see Note 3). No warrants were exercised during the nine months ended September 30, 2018 or 2017. During the nine months ended September 30, 2018, warrants to purchase 170 shares of the Company’s common stock expired. As of September 30, 2018, the Company had these warrants outstanding: Shares Underlying Outstanding Warrants Exercise Price Expiration Date 2,906 $ 120.40 December 1, 2021 3,737 $ 120.40 December 6, 2021 17,190 $ 60.50 January 8, 2020 6,500 $ 10.00 April 4, 2026 3,720,500 $ 3.00 February 15, 2023 3,750,833

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies License and Research Agreements ADVA-Tec License Agreement In March 2017, the Company entered into a license agreement, or the ADVA-Tec Agreement, with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. ADVA-Tec and its affiliates own issued patents or patent applications covering Ovaprene and control proprietary trade secrets covering the manufacture of Ovaprene. As of the date of this report, this patent portfolio includes 12 issued patents worldwide and 8 patent applications, all of which are exclusively licensed to the Company for the human contraceptive use of Ovaprene under the terms of the ADVA-Tec Agreement. The license continues on a country-by-country basis until the later of the life of the licensed patents or the Company’s last commercial sale of Ovaprene. The Company also has a right of first refusal to license these patents and patent applications for additional indications for Ovaprene. The following is a summary of certain terms of the ADVA-Tec Agreement: • Research and Development. ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a Premarket Approval, or PMA, from the United States Food and Drug Administration, or the FDA, and will supply the Company with its requirements of Ovaprene for clinical and commercial use on commercially reasonable terms. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene, and must meet certain minimum spending amounts per year, such amounts totaling $5.0 million in the aggregate over the first three years, to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first. • Milestone Payments. The Company must make payments of up to $14.6 million in the aggregate to ADVA-Tec based on the achievement of specified development and regulatory milestones, which include the completion of a successful Postcoital Clinical Trial Study (as defined in the ADVA-Tec Agreement); approval by the FDA to commence the Phase 3 pivotal human clinical trial; successful completion of the Phase 3 pivotal human clinical trial; the FDA’s acceptance of the filing of a PMA for Ovaprene; the FDA’s approval of the PMA for Ovaprene; obtaining Conformité Européenne Marking of Ovaprene in at least three designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan. The Company is also required to make up to $20 million in the aggregate in commercial milestone payments to ADVA-Tec upon reaching certain worldwide net sales milestones. Because these milestone payments depend upon the successful progress of the Company’s product development programs, the Company cannot estimate with certainty when these payments will occur, if ever. • Royalty Payments. After the commercial launch of Ovaprene, the Company is required to make royalty payments to ADVA-Tec based on aggregate annual net sales of Ovaprene in specified regions, which percentage royalty rate will vary between 1% and 10% and will increase based on various net sales thresholds. • Termination Rights. The ADVA-Tec Agreement includes customary termination rights for both parties and provides the Company the right to terminate with or without cause in whole or on a country-by-country basis upon 60 days prior written notice. ADVA-Tec may terminate the agreement if the Company fails to do any of the following: (i) satisfy the annual spending obligation described above, (ii) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (iii) conduct clinical trials as set forth in the development plan that is agreed by the Company and ADVA-Tec, and as may be modified by a joint research committee, where such failure is not caused by events outside of the Company’s reasonable control, or (iv) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within six months of the production and release of Ovaprene, where non-enrollment is not caused by events outside of its reasonable control. In addition, ADVA-Tec may terminate the ADVA-Tec Agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device deemed competitive to Ovaprene or, in certain limited circumstances, if the Company fails to commercialize Ovaprene in certain designated countries within three years of the first commercial sale of Ovaprene. SST License and Collaboration Agreement In February 2018, the Company entered into a license and collaboration agreement, or the SST License Agreement, with Strategic Science & Technologies-D, LLC and Strategic Science & Technologies, LLC, referred to collectively as SST. Under the SST License Agreement, the Company was required to secure an investment of at least $10 million by March 31, 2018, which it did. The SST License Agreement provides the Company with an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder, or the Field of Use, SST’s topical formulation of Sildenafil Cream, 3.6% as it exists as of the effective date of the SST License Agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products. The following is a summary of certain terms of the SST License Agreement: • Invention Ownership. The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party shall own a 50% undivided interest in all joint inventions. • Joint Development Committee . The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the SST License Agreement. • Development. The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the SST License Agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the SST License Agreement. • Royalty Payments. SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue. • Milestone Payments. SST will be eligible to receive payments ranging from $0.5 million to $18.0 million on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and an additional $10.0 million to $100 million upon achieving certain commercial milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST. • License Term. The Company’s license received under the SST License Agreement continues on a country-by-country basis until the later of 10 years from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the SST License Agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis. • Termination. Each party has customary rights to terminate the SST License Agreement in the event of material uncured breach by the other party. In addition: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including New Drug Application Approval, or NDA Approval, the Company may terminate the SST License Agreement without cause upon 90 days prior written notice to SST; (2) following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA Approval, the Company may terminate the SST License Agreement without cause upon one 180 days prior written notice; and (3) SST may terminate the SST License Agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon 30 days’ notice to the Company if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and does not cure such failure within 60 days of receipt of SST’s notice thereof. Orbis Development and Option Agreement In March 2018, the Company entered into an exclusive development and option agreement, or the Orbis Agreement, with Orbis Biosciences, or Orbis, for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). The Company agreed to pay Orbis $300,000 to conduct the first stage of development work, Stage 1, as follows: $150,000 upon signing the Orbis Agreement, $75,000 at the 50% completion point, not later than 6 months following the date the Orbis Agreement was signed, and $75,000 upon delivery by Orbis of the 6-month batch, not later than 11 months following the date the Orbis Agreement was signed. Upon Orbis successfully completing Stage 1 of the development program and achieving the predetermined target milestones for Stage 1, the Company will have 90 days to instruct Orbis whether to commence the second stage of development work, Stage 2. Should the Company execute its option to proceed to Stage 2, it will have to provide additional funding to Orbis for such activities. Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Orbis will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period. The Orbis Agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful. Juniper Pharmaceuticals - License Agreement In April 2018, the Company entered into an Exclusive License Agreement, or the Juniper License Agreement, with Juniper Pharmaceuticals, Inc., or Juniper, under which Juniper granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Juniper, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Juniper to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under the Juniper License Agreement. The following is a summary of certain terms of the Juniper License Agreement: • Upfront Fee. The Company paid a $250,000 non-creditable upfront license fee to Juniper in connection with the execution of the Juniper License Agreement. • Annual Maintenance Fee . The Company will pay an annual license maintenance fee to Juniper on each anniversary of the date of the Juniper License Agreement, the amount of which will be $50,000 for the first two years and $100,000 thereafter, and which will be creditable against royalties and other payments due to Juniper in the same calendar year but may not be carried forward to any other year. • Milestone Payments. The Company must make potential future development and sales milestone payments of up to $43.8 million (up to $13.5 million in clinical and regulatory milestones and up to $30.3 million in sales milestones) for each product or process covered by the licenses granted under the Juniper License Agreement. • Royalty Payments . During the royalty term, the Company will pay Juniper mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the Juniper Agreement. In lieu of such royalty payments, the Company will pay Juniper a low double-digit percentage of all sublicense income that the Company receives for the sublicense of rights under the Juniper License Agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) 10 years following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country. • Efforts . The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the Juniper License Agreement. • Term . Unless earlier terminated, the term of the Juniper License Agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the Juniper License Agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Juniper may terminate the Juniper License Agreement (1) upon 30 days’ notice for the Company’s uncured breach of any payment obligation under the Juniper License Agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company’s insolvency or the making of an assignment for the benefit of the Company’s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within 90 days, or (4) upon 60 days’ notice for any uncured material breach by the Company of any of its other obligations under the Juniper License Agreement. The Company may terminate the Juniper License Agreement on a country-by-country basis for any reason by giving 180 days’ notice (or 90 days’ notice if such termination occurs prior to receipt of marketing approval in the United States). If Juniper terminates the Juniper License Agreement for the reason described in clause (4) above or if the Company terminates the Juniper License Agreement, Juniper will have full access including the right to use and reference all product data generated during the term of the Juniper License Agreement that is owned by the Company. Pear Tree Acquisition The Company may be required to make certain royalty and milestone payments under the Merger Agreement (see Note 4). Operating Lease The Company entered into a facility lease agreement that commenced on July 1, 2018 for 3,169 square feet of office space for its corporate headquarters. The term of the lease is 37 months and terminates on July 31, 2021. The Company has the option to extend the term of the lease for one year. The gross monthly base rent is $8,873, which will increase approximately 4% per year, subject to certain future adjustments. The base rent was abated during the second month of the lease. Future minimum lease payments at September 30, 2018 total $315,727. The Company recognizes rent expense by the straight-line method over the lease term. As of September 30, 2018, deferred rent totaled $9,292.

Grant Award

Grant Award	9 Months Ended
	Sep. 30, 2018
Grant Award [Abstract]
Grant Award	9. Grant Award In April 2018, the Company received a Notice of Award for the first $224,665 of the anticipated $1.9 million in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health. The award will be applied to clinical development efforts supporting Ovaprene. The balance of the award is contingent upon, among other matters, assessment of the results of the first phase of the research and availability of funds. The Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. As of September 30, 2018, the Company has received payments totaling approximately $144,000. The funding is recognized in the statement of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period. At September 30, 2018, the Company has recorded a receivable of approximately $69,000 for expenses believed to be eligible for reimbursement incurred through September 30, 2018.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company’s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive. The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect: Three months ended Nine months ended September 30, September 30, 2018 2017 2018 2017 Stock options 1,605,790 545,640 1,605,790 545,640 Warrants 3,750,833 30,502 3,750,833 30,502 Total 5,356,623 576,142 5,356,623 576,142

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
Reverse Stock Split	Reverse Stock Split On July 20, 2017, the Company effected a of its common stock.
Use of Estimates	Use of Estimates Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of stock-based compensation, goodwill impairment and purchase accounting. Actual results could differ from those estimates and could materially affect the reported amounts of assets, liabilities and future operating results.
Principles of Consolidation	Principles of Consolidation The interim consolidated financial statements of the Company are stated in U.S. dollars and are prepared using GAAP. These financial statements include the accounts of the Company and its wholly owned subsidiaries, Daré Bioscience Operations, Inc., Daré Bioscience Australia Pty LTD, and Pear Tree Pharmaceuticals, Inc. The financial statements of the Company’s wholly owned subsidiaries are recorded in their functional currency and translated into the reporting currency. The cumulative effect of changes in exchange rates between the foreign entity’s functional currency and the reporting currency is reported in accumulated other comprehensive loss in the interim consolidated balance sheets. All significant intercompany transactions and accounts have been eliminated in consolidation.
Grant Funding	Grant Funding The Company receives certain research and development funding through a grant issued by a division of the National Institutes of Health. The funding is recognized in the statement of operations as a reduction to research and development expense as the related costs are incurred to meet those obligations over the grant period. The Company adopted this policy in 2018. During the three and nine months ended September 30, 2018, the Company recognized approximately $213,000 in the statement of operations as a reduction to research and development expense.
Fair Value Measurements	Fair Value Measurements GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows: • Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities. • Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Cash and cash equivalents of $9.5 million and $7.6 million measured at fair value as of September 30, 2018 and December 31, 2017, respectively, are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.
Recent Pronouncements Not Yet Adopted	Recent Pronouncements Not Yet Adopted In February 2016, FASB issued ASU 2016-02, Leases (Topic 842)
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments , which intended to add or clarify guidance on the classification of certain cash receipts and payments on the statement of cash flows. The new guidance addresses cash flows related to: debt prepayment or extinguishment costs, settlement of zero-coupon bonds, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies and bank-owned life insurance policies, distributions received from equity method investees, beneficial interest in securitization transactions, and the application of predominance principle to separately identifiable cash flows. The standard became effective on January 1, 2018. The Company’s adoption of this standard on January 1, 2018 did not have a material impact on the Company’s interim consolidated financial statements. In January 2017, FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In January 2017, FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350) In May 2017, FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Schedule of Purchase Price Consideration Allocation	The total purchase price consideration of approximately $24.3 million represents the fair value of the shares of Cerulean stock issued in connection with the Cerulean/Private Daré stock purchase transaction and the unamortized fair value of the stock options described above, which was allocated as follows: Purchase Consideration (in thousands) Fair value of shares issued $ 20,625 Unamortized fair value of Cerulean options 3,654 Fair value of total consideration $ 24,279 Assets acquired and liabilities assumed Cash and cash equivalents $ 9,918 Prepaid expense and other current assets 1,915 Accounts payable (233 ) Total assets acquired and liabilities assumed 11,600 Goodwill $ 12,679

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity for Amended 2014 Plan and Related Information	The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the nine months ended September 30, 2018. Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2017 (1) 539,896 $ 31.40 Granted 1,066,050 1.09 Exercised — — Cancelled/expired (156 ) 59.48 Outstanding at September 30, 2018 (unaudited) 1,605,790 $ 11.27 Exercisable at September 30, 2018 (unaudited) 535,031 $ 31.62 (1) Includes 10,149 shares subject to options granted under the 2015 Private Daré Plan assumed in connection with the Cerulean/Private Daré stock purchase transaction.
Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors	Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows: Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Research and development $ 5,494 $ — $ 5,994 $ — General and administrative 34,497 6,947 52,544 6,953 Total $ 39,991 $ 6,947 $ 58,538 $ 6,953
Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors	The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three and nine months ended September 30, 2018 are as follows: Three Months Ended Nine Months Ended September 30, 2018 September 30, 2018 Expected life in years 10.0 10.0 Risk-free interest rate 2.90% 2.90% Expected volatility 123% 123% Forfeiture rate 0.0% 0.0% Dividend yield 0.0% 0.0% Weighted-average fair value of options granted $ 1.03 $ 1.04

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Schedule of Common Stock Warrants Outstanding	As of September 30, 2018, the Company had these warrants outstanding: Shares Underlying Outstanding Warrants Exercise Price Expiration Date 2,906 $ 120.40 December 1, 2021 3,737 $ 120.40 December 6, 2021 17,190 $ 60.50 January 8, 2020 6,500 $ 10.00 April 4, 2026 3,720,500 $ 3.00 February 15, 2023 3,750,833

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share	The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect: Three months ended Nine months ended September 30, September 30, 2018 2017 2018 2017 Stock options 1,605,790 545,640 1,605,790 545,640 Warrants 3,750,833 30,502 3,750,833 30,502 Total 5,356,623 576,142 5,356,623 576,142

Organization and Description _2

Organization and Description of the Business - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2018SegmentClinicalStageAsset
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of operating segments | Segment	1
Number of clinical stage assets assembled as portfolio | ClinicalStageAsset	2

Liquidity - Additional Informat

Liquidity - Additional Information (Detail) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Liquidity [Abstract]
Net loss	$ (2,574,475)		$ (1,629,683)	$ (13,822,263)	$ (2,371,740)
Accumulated deficit	(26,053,215)			(26,053,215)		$ (12,230,952)
Cash and cash equivalents	9,537,463		$ 8,529,220	9,537,463	8,529,220	$ 7,559,846	$ 44,614
Cash flow from operations				$ 7,558,047	$ 1,579,060
Gross proceeds on sale of shares of common stock		$ 11,300,000
Aggregate net proceeds on sales of shares of common stock		$ 10,100,000
Cash received from federal grant	$ 144,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	Jul. 20, 2017	Sep. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)
Significant Accounting Policies [Line Items]
Reverse stock split			1-for-10
Reverse stock split, conversion ratio	0.1
Fair Value, Measurements, Recurring [Member]
Significant Accounting Policies [Line Items]
Cash and cash equivalents		$ 9,500,000	$ 9,500,000	$ 7,600,000
Research and Development Expense [Member]
Significant Accounting Policies [Line Items]
Grant funding recognized during period		$ 213,000	$ 213,000

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($)	May 16, 2018	Apr. 30, 2018	Jul. 19, 2017	Mar. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Business Combination Reverse Merger [Line Items]
Stock option modification approval date					Mar. 19, 2017
Goodwill impairment charge				$ 5,200,000	$ 5,187,519	$ 7,500,000
Goodwill			$ 12,700,000			$ 5,187,519
Pear Tree Pharmaceuticals, Inc. [Member]
Business Combination Reverse Merger [Line Items]
Business combination completed date	May 16, 2018
Merger Agreement entered date		Apr. 30, 2018
Potential cash payment to acquire business	$ 75,000
Consideration amount	$ 132,000
Period of potential cash payment	1 year
Research and Development Expense [Member] | Pear Tree Pharmaceuticals, Inc. [Member]
Business Combination Reverse Merger [Line Items]
Transaction costs	$ 452,000
Cerulean/Private Dare Stock Purchase Transaction [Member]
Business Combination Reverse Merger [Line Items]
Cash and cash equivalents			9,918,000
Unamortized fair value of stock options			3,654,000
Total purchase price consideration			24,279,000
Purchase price adjustments increase in current liabilities			23,609
Purchase price adjustments increase in current assets			225,778
Original goodwill amount acquired			12,900,000
Reduced original goodwill			202,169
Goodwill			12,679,000
Cerulean/Private Dare Stock Purchase Transaction [Member] | General and Administrative Expense [Member]
Business Combination Reverse Merger [Line Items]
Transaction costs			$ 960,000
Private Dare [Member]
Business Combination Reverse Merger [Line Items]
Business combination completed date					Jul. 19, 2017
Stock purchase transaction completion date					Jul. 19, 2017
Stock purchase agreement date					Mar. 19, 2017

Acquisitions - Schedule of Purc

Acquisitions - Schedule of Purchase Price Consideration Allocation (Detail) - USD ($)	Jul. 19, 2017	Dec. 31, 2017
Assets acquired and liabilities assumed
Goodwill	$ 12,700,000	$ 5,187,519
Cerulean/Private Dare Stock Purchase Transaction [Member]
Business Combination Reverse Merger [Line Items]
Fair value of shares issued	20,625,000
Unamortized fair value of Cerulean options	3,654,000
Fair value of total consideration	24,279,000
Assets acquired and liabilities assumed
Cash and cash equivalents	9,918,000
Prepaid expense and other current assets	1,915,000
Accounts payable	(233,000)
Total assets acquired and liabilities assumed	11,600,000
Goodwill	$ 12,679,000

Convertible Promissory Notes -

Convertible Promissory Notes - Additional Information - (Detail) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended	9 Months Ended
	Feb. 28, 2017	Jun. 06, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Debt Conversion [Line Items]
Convertible promissory notes issued					$ 155,000
Private Dare [Member]
Debt Conversion [Line Items]
Note annual interest rate				8.00%
Convertible promissory notes issued	$ 100,000	$ 55,000
Convertible notes issued, per share			$ 0.18727	$ 0.38
Conversion percentage				120.00%
Private Dare [Member] | Convertible Promissory Notes [Member]
Debt Conversion [Line Items]
Interest expense recognized from convertible promissory notes				$ 0	$ 316,804
Private Dare [Member] | Minimum [Member]
Debt Conversion [Line Items]
Percentage of conversion benefit on preferred stock financing				20.00%
Percentage of conversion benefit			125.00%
Private Dare [Member] | Maximum [Member]
Debt Conversion [Line Items]
Percentage of conversion benefit on preferred stock financing				40.00%
Percentage of conversion benefit			140.00%

Stock based compensation - Addi

Stock based compensation - Additional Information (Detail) - USD ($)	Jul. 10, 2018	Mar. 31, 2017	Mar. 31, 2014	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Jul. 19, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding				1,605,790		1,605,790				539,896
Common stock, shares outstanding				11,422,161		11,422,161				6,047,161
Stock options awards granted						1,066,050
Unamortized stock-based compensation expense				$ 1,089,491		$ 1,089,491
Amortized weighted average period						3 years 7 months 6 days
Common stock, shares issued				11,422,161		11,422,161				6,047,161
Cerulean/Private Dare Stock Purchase Transaction [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued				3,140,000		3,140,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				$ 39,991	$ 6,947	$ 58,538	$ 6,953
2015 Stock Incentive Plan [Member] | Private Dare [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options awards granted						0
2015 Stock Incentive Plan [Member] | Stock Options [Member] | Private Dare [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options grant period						10 years
Stock options vesting period						3 years
Stock options outstanding				10,149		10,149					50,000
2015 Stock Incentive Plan [Member] | Restricted Stock [Member] | Private Dare [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to non-employees								200,000	900,000
Common stock, shares outstanding				223,295		223,295
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering period			6 months
Purchase price as percentage of stock price on offering period			85.00%
Stock-based compensation expense						$ 0	$ 0
Amended and Restated 2014 Plan [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding	2,000,000
Share-based compensation description						The number of shares authorized for issuance under the Amended 2014 Plan is 2,046,885, which is the sum of (a) 1,509,463 shares of common stock plus (b) 537,422 shares of common stock subject to awards granted under the 2014 Plan. The number of authorized shares will increase annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) 2,000,000, (ii) 4% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company’s board of directors.
Options to purchase number of outstanding shares of common stock	2,046,885			1,605,790		1,605,790
Number of outstanding shares of common stock authorized	1,509,463
Number of outstanding shares of common stock authorized subject to grant	537,422
Annual percentage increase in outstanding number of common stock	4.00%
Exercise period for stock options after termination date		2 years
Unamortized fair value expense		$ 3,700,000
Common stock reserved for future issuance				451,244		451,244

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of shares
Number of Shares, Outstanding Beginning | shares	539,896
Number of Shares, Granted | shares	1,066,050
Number of Shares, Cancelled/expired | shares	(156)
Number of Shares, Outstanding Ending | shares	1,605,790
Number of Shares, Exercisable | shares	535,031
Weighted-Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 31.40
Weighted Average Exercise Price, Granted | $ / shares	1.09
Weighted Average Exercise Price, Cancelled/expired | $ / shares	59.48
Weighted Average Exercise Price, Outstanding Ending | $ / shares	11.27
Weighted Average Exercise Price, Exercisable | $ / shares	$ 31.62

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail) (Parenthetical) - shares	Sep. 30, 2018	Dec. 31, 2017	Jul. 19, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding	1,605,790	539,896
Private Dare [Member] | Stock Options [Member] | 2015 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding	10,149		50,000

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details) - Stock Options [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 39,991	$ 6,947	$ 58,538	$ 6,953
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	5,494		5,994
General and Administrative Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 34,497	$ 6,947	$ 52,544	$ 6,953

Stock-based Compensation - Su_4

Stock-based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Detail) - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected life in years	10 years	10 years
Risk-free interest rate	2.90%	2.90%
Expected volatility	123.00%	123.00%
Forfeiture rate	0.00%	0.00%
Dividend yield	0.00%	0.00%
Weighted-average fair value of options granted	$ 1.03	$ 1.04

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
	Feb. 28, 2018	Jan. 31, 2018	Mar. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Feb. 15, 2018
Stockholders Equity [Line Items]
Gross proceeds on sale of shares of common stock			$ 11,300,000
Common stock, shares issued and sold	5,000,000
Price per share	$ 0.70
Class of warrant or right exercisable period	5 years
Warrants exercised				0	0
Warrants to purchase common stock expired				170
Accounting Standards Update 2017-11 [Member]
Stockholders Equity [Line Items]
Estimated fair value of warrants, recorded in equity						$ 3,000,000
Maximum [Member]
Stockholders Equity [Line Items]
Warrants to purchase common stock	3,500,000
ATM Sales Agreement [Member]
Stockholders Equity [Line Items]
Gross proceeds on sale of shares of common stock				$ 1,000,000
Offering expenses incurred				$ 336,000
Common stock, shares issued and sold				375,000
ATM Sales Agreement [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Gross proceeds on sale of shares of common stock		$ 10,000,000
Aggregate commission rate		3.00%
Underwritten Offering [Member]
Stockholders Equity [Line Items]
Gross proceeds from offering of common stock and warrants	$ 10,300,000
Underwriters overallotment option to purchase additional shares of common stock and warrants period	30 days
Proceeds from offering of common stock and warrants, net of costs	$ 9,400,000
Exercise Price	$ 3
Underwritten Offering [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Common stock, shares issued and sold	220,500
Warrants to purchase common stock	525,000
Underwriters option to purchase additional shares	750,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Class Of Warrant Or Right [Line Items]
Shares Underlying Outstanding Warrants	3,750,833
Warrants Expiring on December 1, 2021 [Member]
Class Of Warrant Or Right [Line Items]
Shares Underlying Outstanding Warrants	2,906
Exercise Price | $ / shares	$ 120.40
Expiration Date	Dec. 1, 2021
Warrants Expiring on December 6, 2021 [Member]
Class Of Warrant Or Right [Line Items]
Shares Underlying Outstanding Warrants	3,737
Exercise Price | $ / shares	$ 120.40
Expiration Date	Dec. 6, 2021
Warrants Expiring on January 8, 2020 [Member]
Class Of Warrant Or Right [Line Items]
Shares Underlying Outstanding Warrants	17,190
Exercise Price | $ / shares	$ 60.50
Expiration Date	Jan. 8, 2020
Warrants Expiring on April 4, 2026 [Member]
Class Of Warrant Or Right [Line Items]
Shares Underlying Outstanding Warrants	6,500
Exercise Price | $ / shares	$ 10
Expiration Date	Apr. 4, 2026
Warrants Expiring on February 15, 2023 [Member]
Class Of Warrant Or Right [Line Items]
Shares Underlying Outstanding Warrants	3,720,500
Exercise Price | $ / shares	$ 3
Expiration Date	Feb. 15, 2023

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jul. 01, 2018USD ($)ft²	Apr. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Feb. 28, 2018USD ($)	Mar. 31, 2017USD ($)Country	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)
Commitments And Contingencies [Line Items]
Leased rent area | ft²	3,169
Lease expiration date	37 months
Renewal term of lease	1 year
Gross monthly base rent	$ 8,873
Percentage of increase in annual base rent, each year	4.00%
Operating leases, future minimum lease payments						$ 315,727
Deferred rent, total						$ 9,292	$ 392
License and Collaboration Agreement [Member] | SST [Member]
Commitments And Contingencies [Line Items]
Secured investment funding requirement to be fulfilled, date				Mar. 31, 2018
Percentage of rights to inventions by employees under license agreement				50.00%
License agreement, expiration period				10 years
License agreement, termination description						Termination. Each party has customary rights to terminate the SST License Agreement in the event of material uncured breach by the other party. In addition: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including New Drug Application Approval, or NDA Approval, the Company may terminate the SST License Agreement without cause upon 90 days prior written notice to SST; (2) following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA Approval, the Company may terminate the SST License Agreement without cause upon one 180 days prior written notice; and (3) SST may terminate the SST License Agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon 30 days’ notice to the Company if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and does not cure such failure within 60 days of receipt of SST’s notice thereof
License agreement, termination period prior to receipt of approval				90 days
License agreement, termination period after receipt of approval				180 days
License agreement, termination period for applicable license products of applicable countries				30 days
License agreement, termination period due to performance failure				60 days
License and Collaboration Agreement [Member] | Minimum [Member] | SST [Member]
Commitments And Contingencies [Line Items]
Secured investment required for license agreement				$ 10,000,000
Milestone payments, contingent amount				500,000
License and Collaboration Agreement [Member] | Minimum [Member] | Upon Achieving Certain Commercial Milestones [Member] | SST [Member]
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount				10,000,000
License and Collaboration Agreement [Member] | Maximum [Member] | SST [Member]
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount				18,000,000
License and Collaboration Agreement [Member] | Maximum [Member] | Upon Achieving Certain Commercial Milestones [Member] | SST [Member]
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount				$ 100,000,000
Development and Option Agreement [Member] | Orbis [Member]
Commitments And Contingencies [Line Items]
Milestone payments			$ 300,000
Commencement period for stage two upon achievement of stage one			90 days
Development and Option Agreement [Member] | Upon Signing of Development and Option Agreement [Member] | Orbis [Member]
Commitments And Contingencies [Line Items]
Milestone payments			$ 150,000
Development and Option Agreement [Member] | Upon Completion of Fifty Percent Development Not Later Than Six Months [Member] | Orbis [Member]
Commitments And Contingencies [Line Items]
Milestone payments			75,000
Development and Option Agreement [Member] | Upon Delivery of Six Month Batch Development Not Later Than Eleven Months [Member] | Orbis [Member]
Commitments And Contingencies [Line Items]
Milestone payments			$ 75,000
Juniper Pharmaceuticals - License Agreement [Member]
Commitments And Contingencies [Line Items]
License agreement, termination description		Unless earlier terminated, the term of the Juniper License Agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the Juniper License Agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Juniper may terminate the Juniper License Agreement (1) upon 30 days’ notice for the Company’s uncured breach of any payment obligation under the Juniper License Agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company’s insolvency or the making of an assignment for the benefit of the Company’s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within 90 days, or (4) upon 60 days’ notice for any uncured material breach by the Company of any of its other obligations under the Juniper License Agreement. The Company may terminate the Juniper License Agreement on a country-by-country basis for any reason by giving 180 days’ notice (or 90 days’ notice if such termination occurs prior to receipt of marketing approval in the United States). If Juniper terminates the Juniper License Agreement for the reason described in clause (4) above or if the Company terminates the Juniper License Agreement, Juniper will have full access including the right to use and reference all product data generated during the term of the Juniper License Agreement that is owned by the Company.
License agreement, termination period prior to receipt of approval		90 days
Upfront license fee paid		$ 250,000
Annual license maintenance fee payable in first year		50,000
Annual license maintenance fee payable in second year		50,000
Annual license maintenance fee payable thereafter		100,000
Maximum potential milestone payments		$ 43,800,000
License agreement, royalty termination description		terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) 10 years following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country
License agreement, period of continuation from date of first commercial sale of product or process		10 years
License agreement, notice period of termination for breach of payment obligation		30 days
Period of dismissal of bankruptcy petition		90 days
License agreement, notice period of termination for breach of other obligation		60 days
License agreement, notice period of termination		180 days
ADVA Tec Agreement [Member] | License Agreement [Member] | Upon Reaching Certain Worldwide Net Sales Milestones [Member]
Commitments And Contingencies [Line Items]
Milestone payments						$ 20,000,000
ADVA Tec Agreement [Member] | License Agreement [Member] | Ovaprene [Member]
Commitments And Contingencies [Line Items]
Minimum obligation to be paid in number of years					3 years
Prior written notice period for termination of agreement for both parties					60 days
Agreement termination on failing to enroll patient within months of production and release					6 months
Agreement termination period on failing to commercialize in certain designated countries					3 years
ADVA Tec Agreement [Member] | License Agreement [Member] | Minimum [Member]
Commitments And Contingencies [Line Items]
Number of designated European countries | Country					3
Percentage of royalty rate					1.00%
ADVA Tec Agreement [Member] | License Agreement [Member] | Minimum [Member] | Ovaprene [Member]
Commitments And Contingencies [Line Items]
Minimum spending amounts per year					$ 5,000,000
ADVA Tec Agreement [Member] | License Agreement [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Percentage of royalty rate					10.00%
ADVA Tec Agreement [Member] | License Agreement [Member] | Maximum [Member] | Upon Achievement of Specified Development and Regulatory Milestones [Member]
Commitments And Contingencies [Line Items]
Milestone payments						$ 14,600,000
Clinical and Regulatory Milestones [Member] | Juniper Pharmaceuticals - License Agreement [Member]
Commitments And Contingencies [Line Items]
Maximum potential milestone payments		$ 13,500,000
Sales Milestones [Member] | Juniper Pharmaceuticals - License Agreement [Member]
Commitments And Contingencies [Line Items]
Maximum potential milestone payments		$ 30,300,000

Grant Award - Additional Inform

Grant Award - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Apr. 30, 2018	Sep. 30, 2018	Sep. 30, 2018
Grant Award [Line Items]
Cash received from federal grant		$ 144,000
National Institutes of Health [Member] | Eunice Kennedy Shriver National Institute of Child Health and Human Development [Member]
Grant Award [Line Items]
Grants receivable	$ 1,900,000
Cash received from federal grant			$ 144,000
Reimbursement of grant expenses receivable		$ 69,000	$ 69,000
National Institutes of Health [Member] | First Phase of Research And Availability of Funds [Member] | Eunice Kennedy Shriver National Institute of Child Health and Human Development [Member] | Grant [Member]
Grant Award [Line Items]
Revenue from grant for notice of award	$ 224,665

Net Loss Per Share - Potential

Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding	5,356,623	576,142	5,356,623	576,142
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding	1,605,790	545,640	1,605,790	545,640
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding	3,750,833	30,502	3,750,833	30,502